TY - JOUR
T1 - Absorption, disposition, and metabolism of trans-methyl styryl ketone in female B6C3F1 mice
AU - Sauer, John Michael
AU - Bao, Jingqi
AU - Smith, Richard L.
AU - Kuester, Robert K.
AU - Mayersohn, Michael
AU - Sipes, I. Glenn
PY - 1997
Y1 - 1997
N2 - trans-Methyl styryl ketone (MSK; trans-4-phenyl-3-buten-2-one) is a β- unsaturated ketone that has a wide range of uses in industry, as well as consumer products. MSK does not appear to be overtly toxic in animal models, however, it has been shown to be mutagenic in several in vitro assays after S-9 activation. In this study experiments were conducted to characterize MSK absorption, distribution, metabolism, and elimination after iv, oral, and topical administration to female B6C3F1 mice. After iv administration, [14C]MSK (20 mg/kg; 120 μCi/kg) was rapidly cleared from the blood as evidenced by the following pharmacokinetic values (mean ± SD): terminal disposition half-life (t 1/4 ), 7.98 ± 1.72 min; mean residence time, 5.6 ± 1.7 min; steady-state apparent volume of distribution (V88), 3.33 ± 0.75 liters/kg; and systemic body clearance (CL8), 0.53 ± 0.08 liters/min/kg. Within 48 hr, 92.4% of the dose was excreted in the urine and 3.5% in the laces. The major blood metabolites after iv administration were identified by GC-MS as the 4-phenyl-3-buten-2-ol (methyl styryl carbinol), 4-hydroxy-4- phenyl-2-butanone, and benzyl alcohol. After oral administration of [14C]MSK (200 mg/kg; 100 μCi/kg), 95% of the dosed radioactivity was recovered in the urine and 1.2% in the faces within 48 hr. Major urinary metabolites were identified by LC-MS/MS as N-phenylacetyl-l-glycine (35.1% of dose) and N-benzyl-L-glycine (19.1% of dose). Only a small amount of MSK was detected in the blood after oral administration (~0.73 μg/ml at 10 min), and [14C]-equivalents in the blood never exceeded 2.8% of the dose. After topical application of [14C]MSK (250 mg/kg; 50 μCi/kg), approximately 40% of the dose was absorbed and 84.5% of the absorbed dose was excreted into the urine (36% of the total dose). Urinary metabolites were similar to those described for oral administration. Importantly, [14C]-equivalents were not detected in the blood at any time after dermal administration. These results indicate that the rate of MSK clearance is equivalent to its rate of absorption, and tissue exposure to intact MSK is expected to be limited.
AB - trans-Methyl styryl ketone (MSK; trans-4-phenyl-3-buten-2-one) is a β- unsaturated ketone that has a wide range of uses in industry, as well as consumer products. MSK does not appear to be overtly toxic in animal models, however, it has been shown to be mutagenic in several in vitro assays after S-9 activation. In this study experiments were conducted to characterize MSK absorption, distribution, metabolism, and elimination after iv, oral, and topical administration to female B6C3F1 mice. After iv administration, [14C]MSK (20 mg/kg; 120 μCi/kg) was rapidly cleared from the blood as evidenced by the following pharmacokinetic values (mean ± SD): terminal disposition half-life (t 1/4 ), 7.98 ± 1.72 min; mean residence time, 5.6 ± 1.7 min; steady-state apparent volume of distribution (V88), 3.33 ± 0.75 liters/kg; and systemic body clearance (CL8), 0.53 ± 0.08 liters/min/kg. Within 48 hr, 92.4% of the dose was excreted in the urine and 3.5% in the laces. The major blood metabolites after iv administration were identified by GC-MS as the 4-phenyl-3-buten-2-ol (methyl styryl carbinol), 4-hydroxy-4- phenyl-2-butanone, and benzyl alcohol. After oral administration of [14C]MSK (200 mg/kg; 100 μCi/kg), 95% of the dosed radioactivity was recovered in the urine and 1.2% in the faces within 48 hr. Major urinary metabolites were identified by LC-MS/MS as N-phenylacetyl-l-glycine (35.1% of dose) and N-benzyl-L-glycine (19.1% of dose). Only a small amount of MSK was detected in the blood after oral administration (~0.73 μg/ml at 10 min), and [14C]-equivalents in the blood never exceeded 2.8% of the dose. After topical application of [14C]MSK (250 mg/kg; 50 μCi/kg), approximately 40% of the dose was absorbed and 84.5% of the absorbed dose was excreted into the urine (36% of the total dose). Urinary metabolites were similar to those described for oral administration. Importantly, [14C]-equivalents were not detected in the blood at any time after dermal administration. These results indicate that the rate of MSK clearance is equivalent to its rate of absorption, and tissue exposure to intact MSK is expected to be limited.
UR - http://www.scopus.com/inward/record.url?scp=0030793860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030793860&partnerID=8YFLogxK
M3 - Article
C2 - 9321522
AN - SCOPUS:0030793860
SN - 0090-9556
VL - 25
SP - 1184
EP - 1190
JO - Drug Metabolism and Disposition
JF - Drug Metabolism and Disposition
IS - 10
ER -